Sebastian Lewandowski
- Institutionen för klinisk neurovetenskap
- Avdelningen för neuro
- Immunoterapi – Robert Harris forskargrupp
Om mig
2018 - Teamledare vid institutionen för klinisk neurovetenskap.
2008 - 2018 - Postdoktor Ulf Eriksson-gruppen, Karolinska Institutet
2005 - Doktorsexamen. Nencki Institute of Experimental Biology, Warsaw, Polen
1997 - MSc-examen. Universitetet i Gdansk, Polen
Forskningsbeskrivning
Vårt team studerar cellulära mekanismer för cerebrovaskulära skador i ALS neurodegeneration för att hitta nya kliniska biomarkörer och terapeutiska lösningar.
Höjdpunkt i publikationen:
Månberg A. et al. Nature Medicine, April 2021
"Altered perivascular fibroblast activity precedes ALS disease onset".
Nature Medicine News and Views, April 2021
"Is presymptomatic ALS perivascular?"
Karolinska Institutet Pressmeddelande.
"Ny celltyp bidrar till ökad förståelse av ALS"
Vår webbresurs för cellspecifikt genuttryck vid ALS:
https://alscellatlas.org/
Vi tittar på hur dysfunktion i blodkärlen och vaskulär remodellering leder till
ökad svårighetsgrad av amyotrofisk lateralskleros (ALS) och FTD med hjälp av
bioinformatik, in vivo-gnagarmodeller och kliniska prover. Vi samarbetar
med de ledande neurologicentrumen i Europa och USA, inklusive UZ Leuven i
Belgien, Univ. Utrecht i Holland, Univ. Ulm i Tyskland och UCSD i San Diego.
San Diego. Våra resultat leder till nya off-label-läkemedelsapplikationer för behandling och
biomarkörer vid neurodegeneration, inklusive ALS, stroke och multipel skleros.
Vi erbjuder masterstudenter, doktorander och postdoktorer till mycket motiverade och
entusiastiska forskare. För mer information, skicka ett e-postmeddelande till sebastian.lewandowski@ki.se
Undervisning
2020 - pågående. Doktorandkursledare "Den vaskulära hjärnan"
2008 - pågående. Föreläsare och gruppdiskussionsledare i biomedicinprogrammet
2018 - pågående. Handledning av MSc-studenter
Artiklar
- Article: JOURNAL OF CLINICAL INVESTIGATION. 2025;135(5):e171077Protzmann J; Zeitelhofer M; Stefanitsch C; Torrente D; Adzemovic MZ; Matjunins K; Randel SJI; Lewandowski SA; Muhl L; Eriksson U; Nilsson I; Su EJ; Lawrence DA; Fredriksson L
- Article: EBIOMEDICINE. 2024;110:105470Lewandowski SA; Kular L; Jagodic M
- Journal article: CEREBRAL CIRCULATION - COGNITION AND BEHAVIOR. 2024;6:100049Månberg A; Skene N; Sanders F; Szczepinska A; Remnestål J; De Vocht J; Anink J; Vergunst-Bosch H; Rodriguez-Vieitez E; Gilthorpe J; Harris R; Aronica E; Van Damme P; Ludolph A; Veldink J; Ingre C; KTH PN; Lewandowski S
- Article: FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY. 2023;11:1169962Hipke K; Pitter B; Hruscha A; van Bebber F; Modic M; Bansal V; Lewandowski SA; Orozco D; Edbauer D; Bonn S; Haass C; Pohl U; Montanez E; Schmid B
- Article: NEUROTHERAPEUTICS. 2021;18(3):1963-1979Peters S; Kuespert S; Wirkert E; Heydn R; Jurek B; Johannesen S; Hsam O; Korte S; Ludwig FT; Mecklenburg L; Mrowetz H; Altendorfer B; Poupardin R; Petri S; Thal DR; Hermann A; Weishaupt JH; Weis J; Aksoylu IS; Lewandowski SA; Aigner L; Bruun T-H; Bogdahn U
- Journal article: NATURE MEDICINE. 2021;27(7):1308Manberg A; Skene N; Sanders F; Trusohamn M; Remnestal J; Szczepinska A; Aksoylu IS; Lonnerberg P; Ebarasi L; Wouters S; Lehmann M; Olofsson J; von Gohren Antequera I; Domaniku A; De Schaepdryver M; De Vocht J; Poesen K; Uhlen M; Anink J; Mijnsbergen C; Vergunst-Bosch H; Hubers A; Klappe U; Rodriguez-Vieitez E; Gilthorpe JD; Hedlund E; Harris RA; Aronica E; Van Damme P; Ludolph A; Veldink J; Ingre C; Nilsson P; Lewandowski SA
- Article: NATURE MEDICINE. 2021;27(4):640-646Manberg A; Skene N; Sanders F; Trusohamn M; Remnestal J; Szczepinska A; Aksoylu IS; Lonnerberg P; Ebarasi L; Wouters S; Lehmann M; Olofsson J; von Gohren Antequera I; Domaniku A; De Schaepdryver M; De Vocht J; Poesen K; Uhlen M; Anink J; Mijnsbergen C; Vergunst-Bosch H; Hubers A; Klappe U; Rodriguez-Vieitez E; Gilthorpe JD; Hedlund E; Harris RA; Aronica E; Van Damme P; Ludolph A; Veldink J; Ingre C; Nilsson P; Lewandowski SA
- Journal article: DISEASE MODELS & MECHANISMS. 2020;13(5):dmm045310Crivello M; Hogg MC; Jirstrom E; Halang L; Woods I; Rayner M; Coughlan KS; Lewandowski SA; Prehn JHM
- Article: DISEASE MODELS & MECHANISMS. 2019;12(8):dmm040238Crivello M; Hogg MC; Jirstrom E; Halang L; Wood I; Rayner M; Coughlan KS; Lewandowski SA; Prehn JHM
- Article: NEUROBIOLOGY OF DISEASE. 2018;119:26-40Nonneman A; Criem N; Lewandowski SA; Nuyts R; Thal DR; Pfrieger FW; Ravits J; Van Damme P; Zwijsen A; Van Den Bosch L; Robberecht W
- Article: NEUROPHARMACOLOGY. 2018;133:503-511Crivello M; O'Riordan SL; Woods I; Cannon S; Halang L; Coughlan KS; Hogg MC; Lewandowski SA; Prehn JHM
- Article: ACTA NEUROPATHOLOGICA. 2016;131(3):453-464Lewandowski SA; Nilsson I; Fredriksson L; Lonnerberg P; Muhl L; Zeitelhofer M; Adzemovic MZ; Nichterwitz S; Lawrence DA; Hedlund E; Eriksson U
- Journal article: EXPERIMENTAL NEUROLOGY. 2014;257:182-185Abrams MB; Nilsson I; Kjell J; Lewandowski S; Codeluppi S; Eriksson U; Olson L
- Article: PLOS ONE. 2012;7(6):e38760Abrams MB; Nilsson I; Lewandowski SA; Kjell J; Codeluppi S; Olson L; Eriksson U
- Article: CARCINOGENESIS. 2009;30(4):575-579Vedin L-L; Lewandowski SA; Parini P; Gustafsson J-A; Steffensen KR
- Article: ONCOGENE. 2008;27(7):1019-1032Williams C; Edvardsson K; Lewandowski SA; Stroem A; Gustafsson J-A
- Article: ONCOGENE. 2005;24(30):4789-4798Lewandowski SA; Thiery J; Jalil A; Leclercq G; Szczylik C; Chouaib S
- Article: INTERNATIONAL JOURNAL OF CANCER. 2004;110(6):783-787Skrzypczak M; Bieche I; Szymczak S; Tozlu S; Lewandowski S; Girault I; Radwanska K; Szczylik C; Jakowicki JA; Lidereau R; Kaczmarek L
- Article: CANCER LETTERS. 2001;164(2):143-148Giermasz A; Nowis D; Jalili A; Basak G; Marczak M; Makowski M; Czajka A; Mlynarczuk I; Hoser G; Stok T; Lewandowski S; Jakóbisiak M
Alla övriga publikationer
- Review: FRONTIERS IN VETERINARY SCIENCE. 2023;10:1135282Cannon AE; Zurrer WE; Zejlon C; Kulcsar Z; Lewandowski S; Piehl F; Granberg T; Ineichen BV
- Review: FRONTIERS IN NEUROLOGY. 2022;13:947347Zejlon C; Nakhostin D; Winklhofer S; Pangalu A; Kulcsar Z; Lewandowski S; Finnsson J; Piehl F; Ingre C; Granberg T; Ineichen BV
- Preprint: RESEARCH SQUARE. 2021Zejlon C; Nakhostin D; Winklhofer S; Pangalu A; Lewandowski S; Finnsson J; Piehl F; Ingre C; Granberg T; Ineichen BV
- Preprint: BIORXIV. 2021Zeitelhofer M; Stefanitsch C; Protzmann J; Torrente D; Adzemovic MZ; Lewandowski SA; Muhl L; Eriksson U; Nilsson I; Su EJ; Lawrence DA; Fredriksson L
- Conference publication: INTERNATIONAL JOURNAL OF STROKE. 2020;15(1_SUPPL):624-625Zeitelhofer M; Stefanitsch C; Adzemovic M; Sue J; Lewandowski S; Muhl L; Nilsson I; Lawrence D; Fredriksson L
- Review: PHARMACOLOGY & THERAPEUTICS. 2016;167:108-119Lewandowski SA; Fredriksson L; Lawrence DA; Eriksson U
- Book chapter: HORMONAL CARCINOGENESIS IV. 2005;p. 314-320Skrzypczak M; Zagulska-Szymczak S; Lidereau R; Bieche I; Lewandowski S; Radwanska K; Szczylik C; Vidaud M; Jakowicki JA; Kaczmarek L
- Review: FEBS LETTERS. 2002;524(1-3):1-5Lewandowski S; Kalita K; Kaczmarek L
Forskningsbidrag
- Karolinska Institutet1 January 2024 - 1 January 2028Brain scar formation in acute injury and chronic neurodegeneration leads to permanent lesions with dramatic consequences for individual patients and healthcare systems. Previous work has described the scar- forming contributions from glial and infiltrating immune cells. Yet, recent findings challenged this notion and showed that the lesion core is formed by a newly discovered cell type - the brain perivascular fibroblast with glial cells surrounding the injury area. Single cell RNA data suggests that fibroblasts enlarge perivascular space during injury and secrete chemokines facilitating immune cell infiltration. However, without functional interventions in-vivo we still will not understand how the fibroblasts contribute to the newly formed lesions and how they interact with the immune system. We propose to examine the role of the fibroblasts in the brain injury response by examining their contribution to vascular remodeling and immune cell infiltration in an acute model of the BBB opening (Dorian McGavern at NIH) and in ALS neurodegeneration (Sebastian Lewandowski at Karolinska Institute). We propose to deplete the brain fibroblast cells using a recombinant diphtheria toxin. We will first use this approach to examine their role in a brain injury response using an acute model of blood-brain barrier (BBB) opening with focal ultrasound developed by the host lab (Mastorakos et al. Nature 1 Neuroscience 2021) . Finally, since our previous studies showed that the brain fibroblasts are activated in early stages of ALS (Månberg et al. Nature Medicine 2021)2, we will also deplete these cells in a mouse model of ALS to examine their effect on immune infiltration and disease dynamics (see Fig. 1). Completion of the proposed project will allow us to determine how fibroblasts contribute to brain repair versus neurodegeneration. By comparing the contributions of fibroblasts to these two different outcomes, we aim to identify fibroblast programs that may lead to CNS repair therapies.
- Swedish Research Council1 January 2022 - 31 December 2024
- Molecular phenotyping of brain metabolism in asymptomatic ALS/FTD patientsKarolinska Institutet1 January 2022 - 1 January 2024
- Frick Foundation1 January 2021 - 1 January 2022